New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression

References

• Chng W J, Lau L G, Yusof N, Mow B M. Targeted therapy in multiple myeloma. Cancer Control 2005; 12: 91–104
   PubMedGoogle Scholar
• Hideshima T, Anderson K C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2: 927–937
   PubMed Web of Science ®Google Scholar
• Zaidi A A, Vesole D H. Multiple myeloma: an old disease with new hope for the future. CA Cancer J Clin 2001; 51: 273–285
   PubMed Web of Science ®Google Scholar
• Kastrinakis N G, Gorgoulis V G, Foukas P G, Dimopoulos M A, Kittas C. Molecular aspects of multiple myeloma. Ann Oncol 2000; 11: 1217–1228
   PubMed Web of Science ®Google Scholar
• Roodman G D. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655–1664
   PubMed Web of Science ®Google Scholar
• Boccadoro M, Palumbo A, Bringhen S, Merletti F, Ciccone G, Richiardi L, et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002; 87: 846–850
   PubMed Web of Science ®Google Scholar
• Kumar S, Lacy M Q, Dispensieri A, Rajkumar S V, Fonseca R, Geyer S, et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 2004; 34: 485–490
   PubMed Web of Science ®Google Scholar
• Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105: 8–11
   PubMed Web of Science ®Google Scholar
• Kumar S, Rajkumar S V. Thalidomide and dexamethasone: therapy for multiple myeloma. Expert Rev Anticancer Ther 2005; 5: 759–766
   PubMed Web of Science ®Google Scholar
• Katzel J A, Hari P, Vesole D H. Multiple myeloma: charging toward a bright future. CA Cancer J Clin 2007; 57: 301–318
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Blood E, Vesole D, Fonseca R, Greipp P R. Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the eastern cooperative oncology group. J Clin Oncol 2006; 24: 431–436
   PubMed Web of Science ®Google Scholar
• Richardson P G, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist 2007; 12: 664–689
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Tsuyama N, Obata M, M Kawano M. Mitogenic signals initiated via interleukin-6 receptor complexes in cooperation with other transmembrane molecules in myelomas. J Clin Exp Hematop 2006; 46: 55–66
   PubMedGoogle Scholar
• Corey S J, Anderson S M. Src-related protein tyrosine kinases in hematopoiesis. Blood 1999; 93: 1–14
   PubMed Web of Science ®Google Scholar
• Yamanashi Y, Mori S, Yoshida M, Kishimoto T, Inoue K, Yamamoto T, et al. Selective expression of a protein-tyrosine kinase, p56lyn, in hematopoietic cells and association with production of human T-cell lymphotropic virus type I. Proc Natl Acad Sci USA 1989; 86: 6538–6542
   PubMed Web of Science ®Google Scholar
• Hibbs M L, Tarlinton D M, Armes J, Grail D, Hodgson G, Maglitto R, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995; 83: 301–311
   PubMed Web of Science ®Google Scholar
• Nishizumi H, Taniuchi I, Yamanashi Y, Kitamura D, Ilic D, Mori S, et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity 1995; 3: 549–560
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Tsuyama N, Kawano M M. Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules. Int J Hematol 2003; 78: 95–105
   PubMed Web of Science ®Google Scholar
• Zhou Q, Yao Y, Ericson S G. The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells. Int J Hematol 2004; 79: 63–73
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Tsuyama N, Abroun S, Liu S, Li F J, Taniguchi O, et al. Requirements of Src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood 2002; 99: 2172–2178
   PubMed Web of Science ®Google Scholar
• Li Y, Chen W, Ren J, Yu W H, Li Q, Yoshida K, et al. DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7. Cancer Biol Ther 2003; 2: 37–43
   Google Scholar
• Durum S K, Aiello F B. Interleukin-7 induces MUC1. Cancer Biol Ther 2003; 2: 194–195
   PubMed Web of Science ®Google Scholar
• Field-Smith A, Morgan G J, Davies F E. Bortezomib (Velcade™) in the treatment of multiple myeloma. Ther Clin Risk Manag 2006; 2: 271–279
   PubMedGoogle Scholar
• Morgan G J, Davies F E, Cavenagh J D, Jackson G H. United Kingdom Myeloma Forum (UKMF); Haematology Oncology Task Force of the British Committee for Standards in Haematology. Position statement on the use of bortezomib in multiple myeloma. Int J Lab Hematol 2008; 30: 1–10
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M, Irwin D, Stadtmauer E A, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557–3560
   PubMed Web of Science ®Google Scholar
• El-Cheikh J, Michallet M, Nagler A, de Lavallade H, Nicolini F E, Shimoni A, et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica 2008; 93: 455–458
   PubMed Web of Science ®Google Scholar
• Mateos M V, Hernández J M, Hernández M T, Gutiérrez N C, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006; 108: 2165–2172
   PubMed Web of Science ®Google Scholar
• Mateos M V, Hernández J M, Hernández M T, Gutiérrez N C, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008; 93: 560–565
   PubMed Web of Science ®Google Scholar
• San Miguel J F, Schlag R, Khuageva N K, Dimopoulos M A, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906–917
   PubMed Web of Science ®Google Scholar
• Kuhn D J, Chen Q, Voorhees P M, Strader J S, Shenk K D, Sun C M, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110: 3281–3290
   PubMed Web of Science ®Google Scholar
• Koldehoff M, Beelen D W, Elmaagacli A H. Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma. J Leukoc Biol 2008; 84: 561–576
   PubMed Web of Science ®Google Scholar
• Podar K, Shringarpure R, Tai Y-T, Simoncini M, Sattler M, Ishitsuka K, et al. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res 2004; 64: 7500–7506
   PubMed Web of Science ®Google Scholar
• Lombardo L J, Lee F Y, Chen P, Norris D, Barrish J C, Behnia K, et al. Discovery of N-(2-chloro-6-methyl- phenyl)- 2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)- 2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658–6661
   PubMed Web of Science ®Google Scholar
• Bharti A C, Donato N, Aggarwal B B. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003; 171: 3863–3871
   PubMed Web of Science ®Google Scholar
• Luo F R, Barrett Y C, Yang Z, Camuso A, McGlinchey K, Wen M L, et al. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor. Cancer Chemother Pharmacol 2008; 62: 1065–1074
   PubMed Web of Science ®Google Scholar
• Montero J C, López-Pérez R, San Miguel J F, Pandiella A. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. Haematologica 2008; 93: 851–859
   PubMed Web of Science ®Google Scholar
• Chen Z, Lee F Y, Bhalla K N, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 2006; 69: 1527–1533
   PubMed Web of Science ®Google Scholar
• Coluccia A M, Cirulli T, Neri P, Mangieri D, Colanardi M C, Gnoni A, et al. Validation of PDGFR{β} and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib (BMS-354825/Sprycel(R)). Blood 2008; 115: 1346–1356
   Web of Science ®Google Scholar
• Luo F R, Camuso A, McGlinchey K, Fager K, Flefleh C, Wen M L, et al. Evaluation of anti-osteoclastic activity of the novel, oral mutli-targeted kinase inhibitor Dasatinib (BMS-354825). AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics 2005, (Suppl; Abstr B178)
   Google Scholar
• Wildes T M, Ruddell A, Gao F, Uy G, Cashen A, Abboud C, et al. The activity and toxicity of dasatinib in relapsed or plateau-phase multiple myeloma. [Abstract]. Blood 2007; 110: 1182
   Google Scholar
• Mukherjee S, Raje N, Schoonmaker J A, Liu J C, Hideshima T, Wein M N, et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008; 118: 491–504
   PubMed Web of Science ®Google Scholar
• Roodman G D. Bone building with bortezomib. J Clin Invest 2008; 118: 462–464
   PubMed Web of Science ®Google Scholar